Pay Day For Reata As Bardoxolone Progresses For Kidney Disease In Japan
Reata reaps benefit from 2009 licensing deal with Kyowa Hakko Kirin for bardoxolone as transcription factor activator moves into pivotal study for kidney disease in Japan.
You may also be interested in...
GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.
Once suspended due to safety issues, bardoxolone now has completed a Phase II study that showed kidney function benefit in four rare types of CKD. A pivotal study is underway, with another planned and more possible.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.